知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.021 秒)

    Methods and Devices for In Situ Nucleic Acid Synthesis
    1.
    发明申请
    Methods and Devices for In Situ Nucleic Acid Synthesis 有权
    用于原位核酸合成的方法和装置

    公开(公告)号：US20130309725A1

    公开(公告)日：2013-11-21

    申请号：US13700291

    申请日：2011-05-26

    申请人： Joseph Jacobson ,  Senthil Ramu ,  Daniel Schindler

    发明人： Joseph Jacobson ,  Senthil Ramu ,  Daniel Schindler

    IPC分类号： C12P19/34

    CPC分类号： C12N15/1068 ,  C12N15/1093 ,  C12N15/66 ,  C12P19/34

    摘要： Disclosed are compositions, methods and devices for the in situ synthesis of nucleic acids. In an exemplary embodiment, a support-bound oligonucleotide is elongated by addition of one or more nucleotides by hybridization of a partially double-stranded oligonucleotide, ligation and removal of unwanted nucleotides.

    摘要翻译： 公开了用于原位合成核酸的组合物，方法和装置。 在一个示例性实施方案中，通过部分双链寡核苷酸的杂交，连接和去除不需要的核苷酸，加入一个或多个核苷酸来延伸载体结合的寡核苷酸。

    Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
    5.
    发明申请
    Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection 审中-公开
    使用抗CD137抗体作为放射免疫治疗或放射免疫检测试剂的方法

    公开(公告)号：US20060188439A1

    公开(公告)日：2006-08-24

    申请号：US11061295

    申请日：2005-02-18

    申请人： Scott Strome ,  Daniel Schindler ,  Lieping Chen ,  Harry Meade ,  Yann Echelard

    发明人： Scott Strome ,  Daniel Schindler ,  Lieping Chen ,  Harry Meade ,  Yann Echelard

    IPC分类号： A61K51/00 ,  C07K16/46

    CPC分类号： A61K51/1096

    摘要： The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred imbodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers.

    摘要翻译： 本发明涉及重组激动抗体抗人CD137及其糖基化变体的开发和使用方法。 这些抗体作为有效减少实体瘤或其他癌症适应症并防止其复发的抗癌剂和/或免疫调节剂。 预期抗体对其治疗有效的癌症类型还包括白血病和淋巴瘤。 在优选的实施方案中，本发明的重组抗体在转基因动物的牛奶中制备和纯化。 在本发明的另一个优选实施方案中，本发明的激动性抗CD137抗体可以与放射性核素缀合以用于放射免疫检测或放射免疫治疗目的，或与毒素结合以增强各种癌症的治疗性治疗。

    Chimeric receptor genes and cells transformed therewith
    7.
    发明授权
    Chimeric receptor genes and cells transformed therewith 失效
    嵌合受体基因和转化的细胞

    公开(公告)号：US07741465B1

    公开(公告)日：2010-06-22

    申请号：US08084994

    申请日：1993-07-02

    申请人： Zelig Eshhar ,  Daniel Schindler ,  Tova Waks ,  Gideon Gross

    发明人： Zelig Eshhar ,  Daniel Schindler ,  Tova Waks ,  Gideon Gross

    IPC分类号： C07H21/04 ,  C12N15/74 ,  C12N5/00

    CPC分类号： C07K16/32 ,  C07K16/4291 ,  C07K16/44 ,  C07K2317/52 ,  C07K2317/622

    摘要： Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.

    摘要翻译： 适于赋予具有抗体型特异性的淋巴细胞的嵌合受体基因包括编码特异性抗体的单链Fv结构域的第一基因片段和编码全部或部分跨膜和细胞质结构域的第二基因片段，以及任选的细胞外结构域， 的免疫细胞触发分子。 嵌合受体基因当转染到免疫细胞时，将抗体识别位点和免疫细胞触发部分表达到一个连续的链中。 转化的淋巴细胞可用于治疗方法。

    Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
    8.
    发明申请
    Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection 审中-公开
    使用抗CD137抗体作为放射免疫治疗或放射免疫检测试剂的方法

    公开(公告)号：US20080019905A9

    公开(公告)日：2008-01-24

    申请号：US11061295

    申请日：2005-02-18

    申请人： Scott Strome ,  Daniel Schindler ,  Lieping Chen ,  Harry Meade ,  Yann Echelard

    发明人： Scott Strome ,  Daniel Schindler ,  Lieping Chen ,  Harry Meade ,  Yann Echelard

    IPC分类号： A61K51/00 ,  C07K16/46

    CPC分类号： A61K51/1096

    摘要： The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred imbodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers.

    摘要翻译： 本发明涉及重组激动抗体抗人CD137及其糖基化变体的开发和使用方法。 这些抗体作为有效减少实体瘤或其他癌症适应症并防止其复发的抗癌剂和/或免疫调节剂。 预期抗体对其治疗有效的癌症类型还包括白血病和淋巴瘤。 在优选的实施方案中，本发明的重组抗体在转基因动物的牛奶中制备和纯化。 在本发明的另一个优选实施方案中，本发明的激动性抗CD137抗体可以与放射性核素缀合以用于放射免疫检测或放射免疫治疗目的，或与毒素结合以增强各种癌症的治疗性治疗。

    Compositions and Methods For High Fidelity Assembly of Nucleic Acids
    10.
    发明申请
    Compositions and Methods For High Fidelity Assembly of Nucleic Acids 审中-公开
    用于高保真装配核酸的组合物和方法

    公开(公告)号：US20130059296A1

    公开(公告)日：2013-03-07

    申请号：US13592827

    申请日：2012-08-23

    申请人： Joseph Jacobson ,  Daniel Schindler ,  Scott S. Lawton

    发明人： Joseph Jacobson ,  Daniel Schindler ,  Scott S. Lawton

    IPC分类号： C12P19/34 ,  C40B60/14 ,  C40B40/06 ,  C12Q1/68 ,  C40B50/02

    CPC分类号： C12N15/66 ,  C12N15/10 ,  C12N15/1027 ,  C12N15/1031 ,  C12N15/1089 ,  C12P19/34 ,  C12Q2521/301 ,  C12Q2521/501 ,  G16B30/00

    摘要： Aspects of the invention relate to methods, compositions and algorithms for designing and producing a target nucleic acid. The method can include: (1) providing a plurality of blunt-end double-stranded nucleic acid fragments having a restriction enzyme recognition sequence at both ends thereof; (2) producing via enzymatic digestion a plurality of cohesive-end double-stranded nucleic acid fragments each having two different and non-complementary overhangs; (3) ligating the plurality of cohesive-end double-stranded nucleic acid fragments with a ligase; and (4) forming a linear arrangement of the plurality of cohesive-end double-stranded nucleic acid fragments, wherein the unique arrangement comprises the target nucleic acid. In certain embodiments, the plurality of blunt-end double-stranded nucleic acid fragments can be provided by: releasing a plurality of oligonucleotides synthesized on a solid support; and synthesizing complementary strands of the plurality of oligonucleotides using a polymerase based reaction.

    摘要翻译： 本发明的方面涉及用于设计和产生靶核酸的方法，组合物和算法。 该方法可以包括：（1）提供多个在其两端具有限制酶识别序列的平末端双链核酸片段; （2）通过酶消化产生多个具有两个不同和非互补突出端的粘性末端双链核酸片段; （3）用连接酶连接多个内聚端双链核酸片段; 和（4）形成多个内聚端双链核酸片段的线性排列，其中独特的排列包含靶核酸。 在某些实施方案中，多个平末端双链核酸片段可以通过以下方式提供：释放在固体支持物上合成的多种寡核苷酸; 并使用基于聚合酶的反应合成多个寡核苷酸的互补链。